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Abstract
Introduction—Recurrent venous thromboembolism (VTE) occurs infrequently following a 
provoked event but occurs in up to 30% of individuals following an initial unprovoked event. 
There is limited understanding of the biological mechanisms that predispose patients to recurrent 
VTE.
Objectives—To identify whole blood gene expression profiles that distinguished patients with 
clinically distinct patterns of VTE.
Patients/Methods—We studied 107 patients with VTE separated into 3 groups: (1) ‘low-risk’ 
patients had one or more provoked VTE; (2) ‘moderate-risk’ patients had a single unprovoked 
VTE; (3) ‘high-risk’ patients had ≥2 unprovoked VTE. Each patient group was also compared to 
twenty-five individuals with no personal history of VTE. Total RNA from whole blood was 
isolated and hybridized to Illumina HT-12 V4 Beadchips to assay whole genome expression.
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Results—Using class prediction analysis, we distinguished high-risk patients from low-risk 
patients and healthy controls with good receiver operating curve characteristics (AUC = 0.81 and 
0.84, respectively). We also distinguished moderate-risk individuals and low-risk individuals from 
healthy controls with AUC’s of 0.69 and 0.80, respectively. Using differential expression analysis, 
we identified several genes previously implicated in thrombotic disorders by genetic analyses, 
including SELP, KLKB1, ANXA5, and CD46. Protein levels for several of the identified genes 
were not significantly different between the different groups.
Conclusion—Gene expression profiles are capable of distinguishing patients with different 
clinical presentations of VTE, and genes relevant to VTE risk are frequently differentially 
expressed in these comparisons.
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Introduction
Deep vein thrombosis (DVT) or pulmonary embolism (PE), referred to collectively as 
venous thromboembolism (VTE), affects approximately 350,000 to 600,000 individuals in 
the United States each year, and up to 100,000 will die from the thromboembolic event [1]. 
VTE may occur after transient exposures such as a surgical procedure, prolonged 
immobilization, or with the use of certain therapies, such as oral contraceptives and hormone 
replacement therapy, which is referred to as a provoked event [2]. VTE can also occur in the 
absence of any acquired risk factors, which is referred to as an unprovoked, or idiopathic, 
event [1,3,4]. Other factors that may increase an individual patient’s risk for VTE include 
increased age, the presence of a thrombophilia [5], race/ethnicity, and a variety of medical 
conditions [6].
The current standard of care for patients with provoked VTE consists of therapeutic 
anticoagulation for three months [7]. In contrast, for patients with an unprovoked VTE, up to 
30% will sustain a recurrent event within ten years of completing a standard course of 
therapy [3,8]. Consequently, it is recommended to consider an extended course of therapy 
for patients with an initial unprovoked event [7]. Continued anticoagulant therapy has been 
shown in several studies to significantly decrease the risk for recurrent VTE [6–8] but the 
risk of major bleeding in individuals after the first three months of therapy ranges from a 
baseline of 0.3% to ≥2.5% per year [7].
Determining which patients with VTE have a high risk for recurrent events, and balancing 
this risk with the potential for bleeding if anticoagulation is continued, is an important health 
concern. Multiple studies have investigated biomarkers to help predict which patients are at 
a higher risk for recurrent VTE [9]. Current evidence suggests that inherited thrombophilic 
disorders are not helpful to predict which patients with a first unprovoked VTE are at an 
increased risk for recurrent events [10]. In contrast, elevated D-dimer levels obtained after 
completing a standard course of anticoagulant therapy are associated with an increased risk 
for recurrent VTE [11]. Other biomarkers that have been associated with recurrent VTE 
include elevated levels of soluble p-selectin [12] and elevated thrombin generation [13].
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Whole blood gene expression studies have been used in a variety of disorders including 
myocardial infarction and systemic lupus erythematosus [14,15]. We previously used whole 
blood gene expression profiles to distinguish patients with a single VTE from patients with 
recurrent VTE [16], but this study combined patients with provoked and unprovoked events. 
Here we extend this initial study by using clinically well-defined patient groups with the 
objectives of comparing individuals based on the type of VTE (provoked versus 
unprovoked) as well as by the number of events (single versus multiple). We used two 
distinct analytical approaches, class prediction analysis [17–20] and differential expression 
analysis [21] to identify means to distinguish among these patient groups. A group of 
healthy individuals was included to look for genes and pathways that are differentially 
expressed in healthy individuals compared to individuals with different types of VTE.
Material and Methods
Patient Population
Participants were enrolled in 2009 and 2010 at 4 sites participating in the Thrombosis and 
Hemostasis Centers Research and Prevention Network supported by the Centers for Disease 
Control and Prevention (CDC): Duke University Medical Center, Durham NC; Mayo Clinic, 
Rochester MN; University of North Carolina, Chapel Hill NC; and Rutgers Robert Wood 
Johnson Medical School, New Brunswick NJ. This Network consisted of Thrombosis and 
Hemostasis Centers that provided comprehensive specialty care to patients with 
thrombophilia and thrombotic disorders [22]. Study protocol and consent forms were 
approved by Institutional Review Boards at each site and at the CDC.
Patients with at least one VTE, defined as either PE or DVT of the leg or arm, with the first 
event occurring at age 18 years or older, and who were, at the time of enrollment, greater 
than 10 weeks from their most recent VTE, were approached for participation. The diagnosis 
of VTE was reviewed and objectively confirmed by the site investigator, based on clinical 
history and imaging data. Individuals with no prior history of VTE or known inherited 
clotting disorder and similar in age, gender, and race to the VTE case were identified at each 
site and approached to participate as controls. Patients with known antiphospholipid 
syndrome, active or prior malignancy (excluding skin cancer) at the time of VTE diagnosis, 
infection within the past two weeks of enrollment or currently pregnant were not included in 
this study.
Consenting VTE patients were allocated to 3 groups: (1) low-risk, defined as patients who 
had sustained 1 or more provoked VTE with no history of an unprovoked VTE; (2) 
moderate-risk, defined as patients who had sustained a single unprovoked VTE (with or 
without additional provoked VTE); and (3) high-risk, defined as patients who had sustained 
2 or more unprovoked VTE (with or without additional provoked VTE). A provoked event 
was defined as a VTE occurring in a patient with a clear transient acquired risk factor for 
VTE, i.e. VTE occurring within 3 months after trauma, hospitalization, prolonged 
immobilization, or surgery and the post-operative setting; or in patients taking oral 
contraceptives or hormone replacement therapy; or during pregnancy or the post-partum 
period. Unprovoked events were defined as VTE occurring in the absence of any of these 
transient risk factors.
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Patients with more than one VTE (provoked or unprovoked) had distinct clinical events that 
occurred at different points in time. Thromboembolic events affecting more than one 
vascular bed but occurring at the same time were considered to be a single event (e.g., a 
patient presenting with PE and DVT).
Data and Sample Collection
Demographic and clinical information was collected from each participant through chart 
abstraction or in-person interview. Citrated plasma and serum samples were collected for 
each participant, processed, and stored at −80 °C at each site. Blood was simultaneously 
collected in PAXgene RNA tubes and stored according to the manufacturer’s instructions. 
De-identified samples were shipped to the CDC Division of Blood Disorders’ Molecular and 
Hemostasis Laboratories for analysis.
RNA Isolation and Microarray Hybridization
Total RNA was isolated from whole blood drawn into PAXgene tubes using the PAXgene 
Blood RNA kit (PreAnalytiX; Qiagen GmbH-USA). The quality and quantity of the RNA 
was confirmed using the Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE). Samples with an A260/A280 ratio >2.19, or ≤70 ng of RNA, were 
excluded from the final analyses. RT PCR using probes for IL-1beta and CD141 was used to 
check RNA expression levels for several of the initial samples from each of the sites, to 
confirm comparable yields. RNA was amplified and the cRNA was biotinylated using the 
Ambion Illumina TotalPrep RNA Amplification Kit (Life Technologies, Carlsbad, CA). 
Following labeling, cRNA samples were hybridized to Illumina HT-12 V4 Beadchips to 
assay whole genome gene expression with over 47,000 probes against human transcripts.
Microarray Data Processing
A comprehensive quality control process was performed on all arrays using the lumi 
package in Bioconductor in the R environment for statistical computing [23,24]. Quality of 
the raw data was assessed using the percent of probes present, MA plots, boxplots of the 
expression distribution, and heatmaps to visualize the correlation between samples. Samples 
in which the percent of probes present was 15% or less were excluded, and all probes that 
were not detected in greater than 95% of the remaining samples were removed (21,174 out 
of 47,304). The lumi package was also used to perform background corrections, expression 
value log-transformation, and quantile normalization. The data was then filtered without 
regard to phenotype to include only the top 10,000 probes that varied the most among all of 
the samples [25,26] The microarray data files were submitted to NCBI’s Gene Expression 
Omnibus and are accessible through GEO series accession number GSE48000 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48000) [27].
Statistical Analyses
Descriptive statistics of the demographics of the study participants, including means and 
frequencies, were performed using Excel (Microsoft, Redmond, WA). The Mann–Whitney 
nonparametric test in Prism 6 (Graphpad Software Inc., La Jolla, CA) was used to compare 
BMI, the ages of the participants at the time of enrollment, at the time of first VTE, and time 
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since last VTE. Fisher’s exact test (Graphpad Prism 6) was used to compare the gender, race 
and proportion of PE and anticoagulant therapy among the groups. The mean concentrations 
and 95% confidence intervals for the biomarker levels were determined using Graphpad 
Prism 6.
Class prediction was done on the six possible pair-wise comparisons of the four study 
groups using penalized binary regression. Bayesian Factor Regression was used to model 
correlation structure in the expression data [17]. This served as a dimension reduction step in 
which a large number of expression vectors were expressed as a smaller number of factors. 
In addition to reducing the dimension of the data, the factors were closer to being 
independent when compared to the original data, which facilitates model building. Factor 
analysis is unsupervised and, therefore, does not use phenotype labels. The resulting factor 
scores were then used as predictors to build classification models. Penalized regression 
implemented in the glmnet R package was used to build the classification models [18,19]. 
Estimates of prediction accuracy were obtained through leave-one-out cross-validation, 
which provides unbiased estimates of accuracy, and is appropriate for samples sizes in the 
range of the current study [28–30]. Receiver Operating Characteristic curves and the 
corresponding area under the curve (AUC) were generated using Graphpad Prism 6.
Differential expression was also performed on the six possible pair-wise comparisons of the 
four study groups using the limma package in Bioconductor [21]. A false discovery rate of 
0.005 was used to determine which genes were significantly differentially expressed in each 
comparison.
Functional Analysis of Gene Lists Obtained from Differential Expression
DAVID, a program which aides in the functional interpretation of large lists of genes using 
information from a variety of public bioinformatics databases, was used to understand the 
gene ontologies, biological function and pathways associated with the genes identified in the 
differential expression analysis [31,32]. The functional annotation chart tool in DAVID was 
used to determine the top enriched ontologies in the gene lists from the differential 
expression analysis and functional annotation clustering tool in DAVID was used to look for 
ontologies specific to VTE.
Biomarker Testing
Factor XI, annexin A5, sP-selectin, endothelin, and CD46 levels in plasma or serum samples 
collected at the same time as the whole blood RNA sample were determined by ELISA. 
Serum was used for annexin A5, and citrated plasma was used for the other four biomarkers. 
Optical density was measured with a Vmax Kinetic Microplate Reader (Molecular Devices, 
Sunnyvale, CA). The following kits were used: Total Human Coagulation Factor XI Antigen 
Assay (Molecular Innovations MI, USA); Human Annexin V Platinum ELISA kit 
(eBioscience, San Diego CA); Human sP-selectin/CD62P ELISA kit (R&D Systems, 
Minneapolis, MN); Quantitative ELISA Endothelin-1 (ET-1) Immunoassay kit (R&D 
Systems); and the MCP (CD46) ELISA Kit from UscnLife-Science Inc. (Wuhan EIAab 
Science Co, China).
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One hundred and seventy-eight participants were enrolled, but 3 were subsequently 
excluded because they did not meet enrollment criteria (1 in the low-risk group and 2 in the 
moderate-risk group). Of the 175 participants meeting enrollment criteria, 43 participants 
were excluded because ≤15% of the probes were detected in samples from these individuals 
(9 in the low-risk group, 10 in the moderate-risk group, 5 in the high-risk group, and 19 in 
the healthy control group).
Characteristics of the 132 remaining participants with genomic expression data that passed 
quality assessment are shown in Table 1. Individuals in the high-risk and moderate-risk 
groups were older at the time of enrollment, but the age of the individuals at the time of their 
first VTE event did not differ by risk group (Table 1). Five of the low-risk patients had 
sustained more than one provoked VTE, and twelve of the moderate-risk patients had 
sustained one or more provoked events in addition to a single, unprovoked VTE (Table 1). A 
significantly higher proportion of individuals were on anticoagulant therapy at the time of 
enrollment in the high-risk and moderate-risk groups compared to the low-risk group. 
Fifteen individuals in the low-risk group were on warfarin therapy for more than six months, 
for various reasons, including recurrent provoked thrombotic events and ongoing exposure 
to identified risk factors.
Class Prediction Analysis
Class prediction analysis was done on each of the six possible pairwise comparisons (Table 
2). Bayesian Factor Regression Modeling was used to estimate factors based on a given 
signature. The factor scores were used to predict the phenotype, and leave-one-out cross-
validation was used to assess the success of the predictive model (Table 2). The best results 
were obtained for the comparisons between the high-risk and low-risk groups, the high-risk 
group and the healthy controls, and the low-risk group and healthy controls, where the 
AUCs were 0.81, 0.84 and 0.80 respectively. The comparison between the moderate-risk 
group and the healthy controls had an AUC of 0.69, but the comparisons between the 
moderate-risk group and the high-risk and low-risk groups had AUC values of 0.50 and 
0.58, respectively.
Since the individuals in the high-risk and low-risk groups, and the healthy controls, differed 
in age and gender (Table 1), we performed the class prediction analysis using only age and 
gender. These two parameters were not good predictors of the phenotypes, resulting in 
AUC’s of 0.60 or lower suggesting that the age and gender differences were not contributing 
to the class prediction analysis (data not shown). To exclude the possibility that the use of an 
anticoagulant might influence the expression profiles, we also performed these analyses 
excluding those participants in the high-, moderate-, and low-risk groups who were not 
taking warfarin. This did not significantly alter the results (data not shown) suggesting that 
warfarin use was not significantly contributing to our class prediction analysis.
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To explore the biologic differences between the groups, we used differential expression 
analysis to determine which genes were differentially expressed in each of the 6 
comparisons. Since there was a significant difference in age, gender, and BMI among 
several of the groups (Table 1), these parameters were factored into this analysis. Using a 
false discovery rate of 0.005, we found that 3111 gene probes were differentially expressed 
when the high-risk group and healthy controls were compared, and 446 gene probes were 
differentially expressed when the high-risk and low-risk groups were compared. These two 
comparisons had 177 gene probes in common (Table S1).
Only 1 gene (MGC4677, long intergenic non-protein coding RNA 15) was differentially 
expressed in the comparisons between the low-risk group and the healthy controls, and the 
moderate-risk group and the healthy controls. No genes were differentially expressed when 
comparing the moderate-risk group to either the high-risk or the low-risk groups, even when 
false discovery rates of up to 0.25 were used.
Top Significantly Enriched Gene Ontologies
We used the functional annotation chart tool in DAVID to determine the top differentially 
expressed gene ontologies in the comparisons between the high-risk and low-risk groups, 
and the high-risk group and healthy controls. The top ontologies for the high-risk compared 
to the low-risk groups included extrinsic to membrane (GO:0019898) as well as other 
membrane-related and transport-related ontologies (Table S2). The top ontologies for the 
high-risk group compared to healthy controls included intracellular organelle lumen (GO: 
0070013) as well as several mitochondrial-related ontologies (Table S2).
Gene Ontologies Relevant to VTE
We next used the functional annotation clustering tool in DAVID to look at all of the 
ontologies of the differentially expressed genes in these two comparisons. Functional 
annotation clustering groups genes with similar annotation terms including ontologies and 
pathways, providing a way to look at biological mechanisms. Clustering revealed several 
categories of gene ontologies with potential relevance to VTE, including blood coagulation 
(Table 3), immune response (Table S3), and vascular biology (Table S4).
In the coagulation-related category, three genes, CD46 (complement regulatory protein), 
F2RL1 (coagulation factor II receptor-like 1 (PAR2)), and RAB27A (Rab27A, member RAS 
oncogene family) were differentially expressed in the comparisons between the high-risk 
group and the low-risk group as well as the high risk group and healthy controls (Table 3). 
For each of these genes, expression is lower in the high-risk group, compared to either the 
low-risk group or the healthy controls. One additional gene is differentially expressed in the 
high risk vs. low risk comparison, and 21 genes are differentially expressed in the high risk 
vs. healthy controls comparison (Table 3). Several of the genes differentially expressed in 
these two comparisons have been previously identified as being of potential clinical 
relevance in patients with VTE, including, SELP, ANXA5, KLKB1, and F11 [12,33,34] 
(Table 3).
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In the immune-response related category, 14 genes were differentially expressed in both 
comparisons (Table S3). An additional 6 genes were differentially expressed in the 
comparison between the high-risk and low-risk groups, and 122 genes were differentially 
expressed in the comparison between the high-risk group and healthy controls (Table S3). 
Multiple genes differentially expressed in these two comparisons have been previously 
identified as being of potential clinical relevance in patients with VTE, including SELP, IL4, 
and TF.
In the vascular biology-related category, 6 genes were differentially expressed in both 
comparisons (Table S4). An additional 2 genes were expressed in the comparison between 
high-risk and low-risk groups, and 44 genes were differentially expressed in the comparison 
between the high-risk group and healthy controls (Table S4) Several genes unique to this 
category have been associated with VTE, including ANXA2, in patients with 
antiphospholipid syndrome, and HIF1A.
Differentially Expressed Genes in Pathways Relevant to VTE
Twelve genes in the KEGG complement and coagulation cascades pathway (hsa04610) were 
differentially expressed in the high-risk group versus healthy controls comparison (Table 3). 
One of these genes, CD46, is also differentially expressed in the high-risk versus low-risk 
comparison.
Correlation Between Gene Expression and Protein Expression
To investigate whether there was any relationship between gene expression and protein 
levels, we selected five genes relevant to VTE that are differentially expressed in at least one 
of the comparisons (F11, ANXA5, EDN1, SELP, and CD46) and measured the 
corresponding protein levels in plasma or serum (Fig. 1). Factor XI levels were significantly 
higher in the healthy controls compared to the high-risk group (mean plasma protein level 
3761 versus 2707 ng/ml, p = 0.003), and CD46 levels were significantly higher in the high-
risk group compared to the moderate-risk group (mean plasma protein level 1467 versus 
1183 pg/ml, p = 0.042). All other pairwise comparisons were not significantly different (Fig. 
1). The mean concentration and 95% confidence interval of each protein in the 4 study 
groups is shown in Table S5.
Discussion
We used gene expression profiling as an unbiased approach to explore the relationship 
between RNA expression levels and the different clinical phenotypes of VTE. Applying 
class prediction analysis to the gene expression profiles, we obtained the best discrimination 
between patients with recurrent unprovoked VTE (high-risk group) and healthy controls as 
well as individuals with provoked VTE only (low-risk group). We obtained reasonable 
levels of discrimination between patients with a single unprovoked VTE (moderate-risk 
group) and those with provoked VTE only compared to the healthy controls, but 
discrimination was poor between individuals with a single unprovoked VTE and the other 
two VTE groups (Table 2). The moderate-risk group would be expected to be the most 
heterogeneous of the three patient groups in this study. More than 90% of the patients in the 
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moderate-risk group were on anticoagulant therapy at the time of enrollment, and the 
average time from the most recent VTE for this group was 2.17 years (range 0.23 to 7.3). If 
these patients had discontinued anticoagulant therapy, it would be expected that up to a third 
of them would sustain a recurrent, unprovoked VTE within ten years, which would then 
place them in the high-risk group [3,8]. Prospective studies will be necessary to determine 
whether gene expression profiles can identify which patients with a single unprovoked VTE 
are at highest risk for developing a recurrent event after a standard course of anticoagulant 
therapy.
Using differential expression analysis, we found several genes previously identified by 
alternative strategies as potentially having a role in thrombotic disorders (Tables 3, S3, and 
S4). Single nucleotide polymorphisms within F11, SELP and KLKB1 have been found to be 
associated with VTE [34]. The ANXA5 M2 haplotype has been found to be significantly and 
independently associated with the occurrence of DVT [33]. Upregulation of HIF-1a has been 
reported to stimulate recanalization of venous thrombus [35]. Our results confirm that these 
genes are contributing to VTE risk, and that this contribution can be detected at the level of 
RNA expression in whole blood. Correlations between genotype and RNA expression, and 
between RNA and protein expression, will be important to understand the relationship 
between these findings and the risk of recurrent VTE.
In addition to coagulation-related genes, we also found that immune-response genes were 
frequently differentially expressed in our analyses (Table S3). Crosstalk between the 
complement and coagulation cascades has been well established. Proteins in the complement 
cascade can increase the thrombogenicity of blood and coagulation proteins can activate 
components of the complement cascade [36,37]. We identified 12 genes in the coagulation 
and complement cascades that are differentially expressed in the high risk group compared 
to the healthy controls, and one of these genes, CD46, is also differentially expressed in the 
high risk group compared to the low risk group. Seven genes (CD46, CR1, CR2, C5, CFH, 
C1QB and SERPING1) are involved in complement activation. Three genes (CR1, C5, and 
C1QB) were also found to be differentially expressed in peripheral blood mononuclear cells 
in an independent study comparing patients with pulmonary embolism to patients with 
ischemic heart disease [38]. Two of the differentially expressed genes we identified in the 
complement cascade have been linked to thrombotic disorders. Gene mutations in CD46 and 
CFH have been identified in atypical hemolytic uremic syndrome (aHUS), a complement-
mediated form of renal thrombotic microangiopathy [39]. In addition, eculizumab, a 
humanized monoclonal antibody to C5, reduces the rate of thrombotic events in patients 
with paroxysmal nocturnal hemoglobinuria [40].
To assess whether plasma levels of several of the proteins expressed by the genes identified 
by differential expression might be informative, we measured the corresponding levels of 
five proteins that have been previously associated with risk for VTE. Factor XI levels were 
significantly, albeit slightly, higher in the healthy control group compared to the high-risk 
group (Fig. 1), which mirrored the relationship observed in the comparison of RNA 
expression (Table 3). Prior reports have observed a higher risk of VTE in patients with 
elevated levels of Factor XI [41], however, and this observation needs to be replicated in a 
larger patient population with concomitant determination of genetic variants, gene 
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expression and protein levels. Recent reports in the literature have demonstrated that mRNA 
levels cannot be relied on to predict protein abundance [42].
We previously used gene expression profiles to evaluate individuals with single versus 
recurrent VTE [16]. The two patient groups in that study included individuals with provoked 
as well as unprovoked events, resulting in a more heterogeneous mix of phenotypes. 
Nevertheless, a 50 gene probe model could distinguish individuals in the two groups with an 
AUC of 0.75 (95% confidence interval, 0.60 to 0.90). Two genes involved in platelet 
aggregation (IGF1R and PPARD) were included in that model, as well as ten genes involved 
in immune and inflammatory responses. There is one gene in common with our current 
study, SNRK an immune response related gene (Table S3). That study used a different 
platform (Affymetrix), however, which limits the ability to compare results from the two 
analyses. More recently, Wang, et al. [43] used gene expression profiling of peripheral blood 
mononuclear cells on an Agilent microarray to compare 20 patients with PE with 20 age and 
gender matched individuals with ischemic heart disease but without pulmonary embolism. 
They observed increased mRNA expression of L-selectin, ITGAL, and ICAM-1 in 
participants with pulmonary embolism [43].
There are several limitations to this study that merit consideration. First, the individual 
cohorts were clinically heterogeneous, differing by the proportion of patients with PE, the 
time since their most recent event, and the proportion on anticoagulant therapy at the time of 
enrollment (Table 1). Patients were identified as belonging in the individual cohorts by the 
site investigators using pre-defined criteria, however, and were representative of patients 
encountered in clinical practice at the study sites. A second limitation is that we did not 
enroll sufficient patients for an independent validation set. For studies with moderate sample 
sizes, it has been shown that resampling the data provides a more accurate estimate of 
prediction error than splitting the samples into training and validation sets [28–30]. We 
chose this approach, estimating the prediction error using leave-one-out cross-validation, an 
approach that iteratively evaluates each sample and its contribution to the overall model. 
Our final sample size was smaller than our target, primarily due to the fact that almost a 
quarter of the participants (43 of 175) were excluded from the final analysis on the basis of 
sample quality. Sample collection and processing at multiple sites most likely contributed to 
this outcome.
In summary, we have used gene expression profiling to characterize patients with different 
clinical phenotypes of VTE. The profiles obtained distinguish patients with recurrent, 
unprovoked VTE from healthy controls and patients with provoked VTE only, and provide 
insights into approaches that might be useful in the identification of individuals with a single 
thrombotic event who are at highest risk for a recurrent VTE after completing a standard 
course of therapy. Prospective studies are needed to determine the prognostic value of gene 
expression analyses in identifying these high-risk patients and guiding duration of 
anticoagulant therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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AUC area under the curve
C1QB complement component 1, q subcomponent, B chain
C5 complement component 5
CD46 complement regulatory protein
CDC Centers for Disease Control and Prevention
CFH complement factor H
CR1 complement component receptor 1
CR2 complement component receptor 2
DVT Deep vein thrombosis
EDN1 endothelin 1
F2RL1 coagulation factor II receptor-like 1
F11 coagulation factor XI
HIF1A hypoxia inducible factor 1, alpha subunit
ICAM-1 intercellular adhesion molecule 1
IGF1R insulin-like growth factor 1 receptor
IL4 interleukin 4
ITGAL integrin alpha L chain
KEGG Kyoto Encyclopedia of Genes and Genomes
KLKB1 kallikrein B
PE pulmonary embolism
PPARD peroxisome proliferator-activated receptor delta
SELP selectin P
SERPING1 Serpin peptidase inhibitor Glade G (C1 inhibitor)
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Biomarker Levels in the Plasma or Serum of Study Participants. (A) factor XI, (B) annexin 
A5, (C) sP-selectin, (D) endothelin-1 and (E) CD46 levels were measured in plasma or 
serum samples collected at the same time as the PAXgene tubes as described in the Material 
and Methods section. The abbreviations used include: HR, high-risk group; MR, moderate-
risk group; LR, low-risk group; and Con, Healthy controls. The mean and 95% confidence 
intervals are indicated on each graph.
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Table 1
Demographics of the Study Participants.a
Variable High-risk (n = 40) Moderate-risk (n = 33) Low-risk (n = 34) Healthy Controls (n = 25)
Age (years), mean (range) 56 (27–81) 54(21–84) 48 (24–89) 46 (29–70)
Female, n (%) 13 (32) 18 (54) 20 (59) 16 (64)
BMI, mean (range) 33.0 (19.1–47.0) 31.3 (17.1–48.6) 31.9 (19.2–54.0) 28.8 (19.9–43.8)
Race, n (%)
 White 33 (82) 27 (82) 30 (88) 21 (84)
 Black 7 (17) 6 (18) 3 (9) 3 (12)
 Other - - 1 (3) 1 (4)
VTE events per subject, n (%)
  One 0 21 (64) 29 (85)
  Two 25 (63) 10 (30) 5 (15) N/A
  Three 9 (22) 2 (6) 0
  ≥Four 6 (15) 0 0
Pulmonary embolism, n (%) 20 (50) 27 (82) 11 (32) N/A
Age at first event (years), mean (range) 44 (9–74) 50 (17–84) 44 (19–88) N/A
Time since last VTE (years), mean 
(range)
4.76 (0.24–20.98) 2.17 (0.23–7.30) 2.61 (0.22–13.62) N/A
Anticoagulant therapy, n (%)
  Warfarin 35 (88) 29 (88) 21 (62) -
  Other 5 (12) 2 (6) 1 (3) -
  None - 2 (6) 12 (35) 25 (100)
a
Pair-wise comparisons between the study groups were significantly different for the following comparisons. Age: Individuals in the high-risk 
group were significantly older than those in the healthy control (p = 0.01) and the low-risk group (p = 0.03), and individuals in the moderate-risk 
group were significantly older than those in the healthy control group (p = 0.04). BMI: Individuals in the high-risk group were significantly larger 
than those in the healthy control group (p = 0.017). Sex: There were fewer females in the high-risk group than the low-risk group (p = 0.03) or the 
healthy controls (p = 0.02). Type of VTE: More individuals in the moderate-risk group had PE compared to the high-risk (p = 0.006) and low-risk 
groups (p < 0.0001). Time since the last VTE was significantly longer for individuals in the high-risk group compared to the moderate-risk (p = 
0.05) and low-risk groups (p = 0.03). Anticoagulant therapy: More individuals were on anticoagulant therapy in the high-risk and moderate-risk 
groups compared to the low-risk group (p = <0.0001 and p = 0.005, respectively).
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Table 2
Leave-one-out Cross Validation of Class Prediction using Factors with Penalized Regression.
Comparison Total Participants in Each Set Number Classified Correctly Class error rate AUC of ROC curve
High-risk vs. 40 37 0.07 0.50
Moderate-risk 33 1 0.96
High-risk vs. 40 31 0.22 0.81
Low-risk 34 24 0.29
High-risk vs. 40 36 0.10 0.84
Healthy Controls 25 19 0.24
Moderate-risk vs. 33 18 0.45 0.58
Low-risk 34 18 0.47
Moderate-risk vs. 33 29 0.11 0.69
Healthy controls 25 16 0.36
Low-risk vs. 34 33 0.03 0.80
Healthy Controls 25 12 0.25
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Table 3
Differentially Expressed Coagulation Related Genes.a
Gene Symbol HR vs. LRb,c Expressed higher in HR vs. Conb,c Expressed higher in
Differentially expressed in both comparisons
F2RL1 Yes Low-risk Yes Controls
RAB27A Yes Low-risk Yes Controls
CD46d Yes Low-risk Yes Controls
Differentially expressed in HR vs. LR only
STXBP3 Yes Low-risk No ------------------
Differentially expressed in HR vs. Con only
KLKB1d No ------------------ Yes High-risk
GP1BA No ------------------ Yes High-risk
SERPINA1d No ------------------ Yes High-risk
ANXA5 No ------------------ Yes Controls
ANXA2 No ------------------ Yes Controls
EDN1 No ------------------ Yes High-risk
F11d No ------------------ Yes Controls
SELP No ------------------ Yes High-risk
SERPING1d No ------------------ Yes High-risk
EFEMP2 No ------------------ Yes High-risk
DTNBP1 No ------------------ Yes High-risk
PLAURd No ------------------ Yes High-risk
KIAA1715 No ------------------ Yes High-risk
HPS5 No ------------------ Yes High-risk
C1QBd No ------------------ Yes High-risk
CR1d No ------------------ Yes Controls
CR2d No ------------------ Yes Controls
C5d No ------------------ Yes High-risk
CFHd No ------------------ Yes High-risk
BDKRB1d No ------------------ Yes High-risk
VWA3B No ------------------ Yes High-risk
a
The following gene ontology terms were used to identify genes related to coagulation in the two comparisons: GO:0050817 ~ coagulation, GO:
0007596 ~ blood coagulation, and GO:0030193 ~ regulation of blood coagulation and the interpro term, IPR002035:von Willebrand factor, type A.
b
“Yes” indicates that the gene is differentially expressed; “No” indicates that it is not differentially expressed.
c
Abbreviations used in this table: HR, high-risk and LR, low-risk; and Con; healthy controls.
d
Indicates that the gene is also in the KEGG pathway hsa04610: coagulation and complement cascades.
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